COVID-19 trials registries data warehouse

http://www.chictr.org.cn/showproj.aspx?proj=132731

Wei Jia

weijia19631225@163.com

2021-08-31

Recruiting

nonRCT

Non-randomized

Sequential assignment

Not reported

single-center

Prevention

1. The participants were 18 to 75 years old, male or female, 2. Two doses of inactivated SARS-CoV-2 vaccine were administered recently and the interval between two doses was 3-5 weeks, 3. The neutralization antibody levels were negative or less than 20% average antibody level of COVID-19 recovered patients in 14 days after administering two doses of SARS-CoV-2 vaccine, 4. It is now in 4-24 weeks after administering second dose of SARS-CoV-2 vaccine, 5. Participants can follow the researchers guidance to accomplish the research process.

1. The history of SARS-CoV-2 infection, 2. The History of vaccination against other types of SARS-CoV-2 vaccine other than inactivated SARS-CoV-2 vaccine, 3. Severe mental and neurological disease, 4. The following common disease (coronary heart disease, hypertension, diabetes, chronic respiratory diseases, tumors, etc.) and poorly controlled, 5. Immune deficiency or immunosuppressive therapy patients, 6. According to the researchers, any other factors that the subjects do not fit to participate in this clinical trials.

1

The Afiliated Hospital of Yunnan University

18

75

China

Healthy volunteers

N/A

500

Neutralizing antibody level;Antigen-specific memory T cells;

Phase 4

[{"arm_notes": "third dose;4-24 weeks", "treatment_id": 1923, "treatment_name": "Inactivated sars-cov-2 vaccine (vero cell)", "treatment_type": "Inactivated virus", "pharmacological_treatment": "Vaccine"}]